[HTML][HTML] Complexities of prostate cancer
Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …
[HTML][HTML] Therapy considerations in neuroendocrine prostate cancer: what next?
H Beltran, F Demichelis - Endocrine-Related Cancer, 2021 - erc.bioscientifica.com
Lineage plasticity and histologic transformation to small cell neuroendocrine prostate cancer
(NEPC) is an increasingly recognized mechanism of treatment resistance in advanced …
(NEPC) is an increasingly recognized mechanism of treatment resistance in advanced …
[HTML][HTML] Engineering prostate cancer in vitro: what does it take?
A key challenge in the clinical management and cause of treatment failure of prostate cancer
(PCa) is its molecular, cellular and clinical heterogeneity. Modelling systems that fully …
(PCa) is its molecular, cellular and clinical heterogeneity. Modelling systems that fully …
[HTML][HTML] From omics to multi-omics approaches for in-depth analysis of the molecular mechanisms of prostate cancer
E Nevedomskaya, B Haendler - International Journal of Molecular …, 2022 - mdpi.com
Cancer arises following alterations at different cellular levels, including genetic and
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …
[HTML][HTML] HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
B Biersack, B Nitzsche, M Höpfner - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Epigenetic mechanisms play an important role in the development and persistence of
cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting …
cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting …
Future directions for precision oncology in prostate cancer
K Mizuno, H Beltran - The Prostate, 2022 - Wiley Online Library
Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …
[HTML][HTML] Whole-exome sequencing reveals a comprehensive germline mutation landscape and identifies twelve novel predisposition genes in Chinese prostate …
Prostate cancer is the most inheritable cancer with approximately 42% of disease risk
attributed to inherited factors by studies of twins, indicating the importance of additional …
attributed to inherited factors by studies of twins, indicating the importance of additional …
[HTML][HTML] Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
G Chakraborty, K Gupta, N Kyprianou - nature communications, 2023 - nature.com
Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation
therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is …
therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is …
Methylation status of various gene loci in localized prostate cancer: novel biomarkers for diagnostics and biochemical recurrence
Background Oncologic outcomes for patients with localized prostate cancer (PCa)
undergoing radical prostatectomy (RP) can vary widely. Hypermethylation of tumor …
undergoing radical prostatectomy (RP) can vary widely. Hypermethylation of tumor …
LSD1 Inhibition Disrupts Super-Enhancer–Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer
The lysine demethylase LSD1 (also called KDM1A) plays important roles in promoting
multiple malignancies including both hematologic cancers and solid tumors. LSD1 targets …
multiple malignancies including both hematologic cancers and solid tumors. LSD1 targets …